Navigation Links
Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
Date:11/14/2007

Following the Screening and the Testing of Hundreds of MicroRNAs, Eight MicroRNAs Were Identified that Effectively Reduce Liver Cancer Cell Growth

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, November 14 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today the initiation of in vivo studies in its microRNA-based liver cancer therapeutic program conducted in collaboration with Isis Pharmaceuticals(1) (NASDAQ: ISIS). The project, combining Isis's extensive know how and IP in antisense chemistry and Rosetta Genomics' know how and proprietary microRNA platform technologies, is the companies' leading attempt at harnessing microRNAs' role as master switches of the human body to develop a treatment for cancer.

Out of hundreds of potential microRNAs screened and tested, eight have been identified to lead to a decrease in liver cancer cell growth when inhibited. These microRNAs will be further tested during the in vivo studies.

Liver cancer is the third most common cause of cancer deaths in men and the tenth most common in women, according to the National Cancer Institute. Approximately 20,000 people will die this year of liver cancer in the US alone.

"Rosetta and Isis decided two years ago to focus on developing a microRNA-based drug for this deadly cancer," noted Amir Avniel, CEO and President of Rosetta Genomics. "We are proud to present these results, demonstrating that microRNAs play a key role in liver cancer, and that targeting them in vitro leads to a decrease in cancer cell growth. We look forward to starting the in vivo studies."

Data on this program was presented by the two companies at the American Association for Cancer Research (AACR) conference; "The Rol
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
8. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
9. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
10. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
11. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 Express ... Supplies Pty Ltd are pleased to announce a ... the Australian and New Zealand distributor of DrugCheck® onsite ... Supercar Team participated in the Austin 400 May 17-19 ... into an agreement that involves each car of the ...
(Date:5/22/2013)... 2013 Envera announced today that Michael ... Mr. McErlean has an extensive background in cell production ... his career. , Mike Matheny, President and ... have Mike join our team”. “Mike’s background is perfectly ... fermentation and downstream processing equipment”, added Matheny. “Mike’s ...
(Date:5/22/2013)... Canada (PRWEB) May 22, 2013 ... approaches for deciphering the information they encode. There ... ribosome profiling (deep sequencing of ribosome protected fragments) ... in vivo. , Keynote speakers include Dr. Jonathan ... Francisco and the Howard Hughes Medical Institute, who ...
(Date:5/21/2013)... 2013 First patients dosed with ... bromide designed using Prosonix, particle engineering platform ... of inhaled Respiratory Medicines by Design , has ... will assess its effect on lung function and the ... moderate to severe chronic obstructive pulmonary disease (COPD). The ...
Breaking Biology Technology:Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Envera Appoints Michael McErlean Fermentation Manager 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... new biochip technology could eliminate animal testing in the ... in the development of new pharmaceuticals, according to new ... Institute, the University of California at Berkeley, and Solidus ... will be featured in the online Early Edition of ...
... hemostasis kit combines two important surgical tools: Baxter,s ... human thrombin ... Baxter Healthcare,Corporation today announced the Food and Drug Administration ... and human,thrombin). GELFOAM Plus is the only available hemostasis ...
... (NASDAQ: ANPI , TSX: ANP), a global ... it has submitted a 510(k),application to the U.S. ... 5-Fluorouracil-coated (5-FU) Central Venous,Catheter (CVC)., "We are ... application to,the FDA for our 5-FU CVC, as ...
Cached Biology Technology:Biochip mimics the body to reveal toxicity of industrial compounds 2Biochip mimics the body to reveal toxicity of industrial compounds 3Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 2Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 3Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 4Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 2Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 3Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 4Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC 5
(Date:5/22/2013)... endanger the whole organism, as they may lead to ... Munich now report how byproducts of respiration cause mispairing ... in our cells controls the form and function of ... this are encoded in the linear sequence of the ... cytosine (C), guanine (G) and thymine (T). Random changes ...
(Date:5/22/2013)... and wild plants have slowed in recent years, according ... University of Leeds and the Naturalis Biodiversity Centre in ... the diversity of species in Britain, Belgium and the ... picture brightened markedly after 1990, with a slowdown in ... wild plants. , Professor Bill Kunin, Professor ...
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... Boston University School of Medicine (BUSM) faculty members, ... and psychiatry and Michael Silverstein, MD, an associate ... National Institute of Mental Health (NIMH) Biobehavioral Research ... ten other investigators from around the country. The ...
... everyday life and are involved in leisure activities rarely ... University of Gothenburg, Sweden. Occupational therapist Christina Andersson, ... life affects alcohol consumption as part of the wider ... has been ongoing at the Sahlgrenska Academy since the ...
... system can affect healthy people,s personality traits as well ... behaviour, reveals a thesis from the University of Gothenburg, ... and is responsible for defending humans against infection as ... therefore vital for our survival. Research has demonstrated that ...
Cached Biology News:Boston University School of Medicine researchers receive NIMH brain awards 2Women involved in leisure activities drink less alcohol 2Genes of the immune system are associated with increased risk of mental illness 2
... for maximum packaging efficiencies of T7Select vectors ... (> 109 pfu/g with control DNA) make ... at least 5 107 recombinant plaques ... from a specially designed phage that reduces ...
... Tecan has 20 years of expertise in ... and still offers the most powerful systems ... up to 40 000 in-microplate tests requiring ... integration of different modules (such as worktable ...
... Luciferase-based ENGENISTM (Entire Gene/cDNA or Isolated ... provide a quantitative approach for evaluation of ... serve as an efficient target for RNA ... algorithms are not perfect, leaving the probability ...
... pre-validated SNP sequencing services ... within 93 genes including ... more than 80 tyrosine ... were developed and validated ...
Biology Products: